Amicidin-β topical solution - 15 mL
DrugAmicidin-β topical solution for local administration - 15 mL
NCT Number: NCT07379684
The goal of this Phase 1 clinical trial is to learn about the safety profile of Amicidin-β topical solution applied directly into infected surgical or traumatic wounds during a surgical procedure. The main questions it aims to answer are:
1. Is Amicidin-β topical solution safe to test in larger clinical trials? 2. Is Amicidin-β topical solution absorbed into the bloodstream from local wound application? 3. Is Amicidin-β topical solution easy for the surgeon to use? Participants will receive either standard of care alone, or standard of care with intrawound Amicidin-β topical solution for the management of their wound infection. Researchers will compare these two groups (standard of care alone to standard of care with Amicidin-β topical solution) to see if there are any study drug-related adverse effects.
Interested in participating?
Request Info18 year–79 year
All sexes
Interventional
Phase 1
Lundquist Institute, Torrance, California, United States
This is a Standard of Care (SOC)- controlled study of approximately 44 patients divided into three sequential cohorts of 8, 12, and 24 patients. Within each sequential cohort, patients will be randomized to SOC only or to SOC plus Amicidin-β topical solution in a 1:3 ratio.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Main Inclusion Criteria:
Main Exclusion Criteria:
Patients with any of the following will be excluded:
Amicidin-β topical solution for local administration - 15 mL
Amicidin-β topical solution for local administration - 50 mL
Per institutional Standard Of Care
Time frame: From Day 1 to Day 30
Time frame: From Day 1 to Day 30
Time frame: From Day 1 to Day 3
Systemic absorption will be assessed by single molecule array (Simoa) immunoassay measurements of patient plasma.
Contact information is provided by the study sponsor or research team.
Daniel J Gowen-Huang, MBA
CONTACT
Michael P Bevilacqua, MD, PhD
CONTACT
Macro Biologics, Inc.
Industry
A Phase 1 Study to Assess Safety and Tolerability of Amicidin-β Topical Solution in Adult Patients Undergoing Interventional Management of a Surgical or Traumatic Wound Infection
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07651462
Arthritis, Arthroplasty, Replacement, Hip
Berlin, State of Berlin, Germany
View Trial DetailsNCT07524062
Infections, Neoplasms
Leuven, Vlaams Brabant, Belgium
View Trial DetailsNCT07040683
Bandages, Infections
Malmö, Sweden
View Trial DetailsNCT07382973
Endocrine System Diseases, Infections
Ocoyoacac, State of Mexico, Mexico
View Trial Details